![](https://investorshub.advfn.com/uicon/32556.png?cb=1490101632)
Saturday, May 09, 2009 10:19:03 AM
http://anti-ps.blogspot.com
http://anti-ps.blogspot.com/2009/05/anti-ps-asco-and-glenn-dranoff-interim.html
Interim data from a phase II clinical trial evaluating anti-PS in advanced breast cancer patients is slated for an oral presentation at the annual ASCO conference this year, (abstract #3005 [6-1-09 10:30am]).
Of note, immediately following the anti-PS presentation, the discussion of the three preceding presentations, (abstracts 3003-3005), is led by none other than Dr. Glenn Dranoff himself, well-known and well-published Harvard immunologist, who recently has been studying the therapeutic anti-tumor effects achieved by blocking PS-mediated signaling.
Dranoff's 2008 paper published in the journal Clinical Cancer Research, titled ”Capitalizing on the Immunogenicity of Dying Tumor Cells”, should be "required reading" for anyone interested in how exposed PS is exploited by tumors to elude the cells of the immune system. In the paper, he speaks very broadly about the role of exposed PS in the apoptotic process common to all multicellular organisms, and he outlines experiments in which autologous tumor cells combined with PS-blocking yielded some very impressive experimental anti-tumor results.
3-15-08 CCR: http://clincancerres.aacrjournals.org/cgi/content/full/14/6/1603
Also worth reading is Dranoff's recent WIPO patent application, in which he discusses tumor vaccines utilizing autologous tumor cells altered to express GM-CSF, combined with PS signaling blockers - including anti-PS antibodies.
http://tinyurl.com/qhtk9r
= = = = = = = =
Dr. Glenn Dranoff profile: http://tinyurl.com/rbfar6
…Associate Professor of Medicine, Harvard Medical School
= = = = = = = = = = = = =
ASCO 2009 PROGRAM BY-DAY (231-pg PDF): http://tinyurl.com/cn9qlc
MON. 6-1-09 9am-12pm, Abstract #3005 (pg.248)
[updated prelim. data from the ongoing Ph.2 Bavi+Doce/MBC/GA. trial]…
ORAL ABSTRACT SESSION
Track: Developmental Therapeutics: Immunotherapy
10:30am: “Phase II Study of Bavituximab + Docetaxel in Patients with Locally Advanced or Metastatic Breast Cancer”
D. Tabagari [PI, GA. Ph.2 Trial], G. Nemsadze, M. Jincharadze, M. Janjalia, J. S. Shan [PPHM VP/Clin.Affairs]
- - - - - - - -
***Note: Immediately the Bavi Oral, “10:45am Discussion on Abstracts 3003-3005”, led by Dr. Glenn Dranoff, MD, Dana-Farber Cancer Institute, “Cancer Vaccines”
- - - - - - - -
2-12-08 PR (Ph.2 Bavi+Doce/Breast GA: 1st-Dosage): "Bavituximab represents a novel strategy for the treatment of cancer that has demonstrated encouraging potential in initial clinical studies," said David Tabagari, M.D., Ph.D., the head of Medulla Immunotherapy & Chemotherapy Clinic and P.I. of the bavituximab breast cancer trial being conducted in the Republic of Georgia. "We are pleased to have the opportunity to conduct the 1st Phase II trial of this potentially valuable new approach to treating cancer." http://tinyurl.com/36c28s
MON. 6-1-09 1-5pm, Abstract #1080 (pg.268)
[updated prelim. data from the ongoing U.S. Ph.1 Bavi-Mono Solid-Tumors trial]…
GENERAL POSTER SESSION
Track: Breast Cancer - Metastatic
“Phase I Study of Bavituximab, a Novel Anti-Phosphatidylserine Monoclonal Antibody in Patients with Advanced Refractory Cancer: Preliminary Results”
N. K. Ibrahim [MDA], L. Wong, L. Rosen, J. Shan [PPHM VP/Clin.Affairs]
• N.K. Ibrahim/PI: MDA, Breast Cancer Specialist http://tinyurl.com/clpu25
• Lucas Wong/PI: Scott&White, Co-Dir./Gastro-Int. Oncology http://tinyurl.com/dfr44x
• Lee Rosen/PI: Premier Oncology, Hematology & Oncology http://tinyurl.com/p77uu
• Joe Shan, VP/Reg&Clinical-Affairs, PPHM http://tinyurl.com/2r5h6u
ASCO Home: http://www.asco.org
3-12-09, S.King/J.Shan comments on ASCO’09: http://tinyurl.com/crl27y
On ASCO’s view of PRELIM-DATA & significance of ORAL-PRES: http://tinyurl.com/r6sdpt & http://tinyurl.com/oodcg7
History of ALL Bavi Mono & Combo Cancer Trials – see iBox at this link:
http://investorshub.advfn.com/boards/board.aspx?board_id=2076
Recent CDMO News
- Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024 • GlobeNewswire Inc. • 09/03/2024 08:05:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2024 08:30:10 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 08/28/2024 08:34:04 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 08/28/2024 08:32:18 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/28/2024 08:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:50:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:48:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 08:40:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 08:30:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 12:23:26 AM
- Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024 • GlobeNewswire Inc. • 07/02/2024 08:05:04 PM
- Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024 • GlobeNewswire Inc. • 07/01/2024 11:00:21 AM
- Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance • GlobeNewswire Inc. • 05/23/2024 12:05:46 PM
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
Simple Stock Loans Announces Unique Solutions For Investors Looking for Alternative Liquidity Amidst Recent Small Cap Rally Sep 6, 2024 9:30 AM
Reliant Coffee Debuts at #271 on the Inc. 5000 List of Fastest Growing Companies - Coffee Service Industry Disruptor Brews Up Exponential Growth Sep 5, 2024 11:51 AM
VAYK Confirms Receiving Revenue from First Airbnb Property with 1.4 Million Annual Revenue Goal • VAYK • Sep 4, 2024 9:34 AM
Mawson Finland Limited Expands Known Mineralized Zones at Rajapalot: New Lens Intercepts 21.75 m at 5.25 g/t Gold & 515 ppm Cobalt • MFL • Sep 4, 2024 9:02 AM
Integrated Ventures Acquires 51% Stake In GetTrim.Com (TM), Telemedicine Platform With Focus On Expansion Into Booming GLP-1 Powered Weight Loss Market • INTV • Sep 4, 2024 8:45 AM
Avant Technologies Announces Strategic Review Process Intended to Maximize Shareholder Value • AVAI • Sep 4, 2024 8:00 AM